IJMPR does now not suggest any product or carrier marked as an commercial or promoted by using a sponsor in publications. Editorial content material is no longer compromised via industrial or economic interests, or by means of any precise preparations with marketing customers or sponsors.
The editorial board of the journal does now not receive for consideration and does no longer print advertising and marketing articles (both on a reimbursable and free basis).
Authors of the scientific articles can't hyperlink to advertisements the use of keywords.
Informed Consent Policy-
Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Authors should disclose to these patients whether any potential identifiable material might be available via internet as well as in print after publication. Nonessential identifying details should be omitted.
IJMPR decides that patient confidentiality is better guarded by having the authors archive the consent, and instead providing us with a written statement in the manuscript attesting that they have received and archived written patient consent. When informed consent has been obtained, it should be indicated later in the published article.
IJMPR is an international open access source for a high quality and peer reviewed journal in the fields of Medical and Pharmaceutical Sciences. IJMPR publishes research papers across all academic disciplines in the fields of Medical, Pharmaceutical Sciences.